Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

yonkenafil

Known as: 2-(2-ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)phenyl)-5-methyl-7-propyl-3H-pyrrolo(2,3-d)pyrimidin-4(7H)-one 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Intracerebroventricular (icv) streptozotocin (STZ) injection decreases cerebral insulin signal pathway function and produces… Expand
2016
2016
Yonkenafil is a promising drug for treatment of male erectile dysfunction. Previous studies showed that the piperazine-N,N… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
2015
2015
In Alzheimer's disease (AD), activated microglia invade and surround β-amyloid plaques, possibly contributing to the aggregation… Expand
2015
2015
Our previous studies showed that the phosphodiesterase-5 (PDE5) inhibitor sildenafil inhibited the microglial activation induced… Expand
  • figure 1
  • figure 3
  • figure 4
  • figure 5
2014
2014
  • Xuemei Chen, Nannan Wang, +6 authors Jingyu Yang
  • Experimental Neurology
  • 2014
  • Corpus ID: 24713194
Yonkenafil is a novel phosphodiesterase type 5 (PDE5) inhibitor. Here we evaluated the effect of yonkenafil on ischemic injury… Expand
2008
2008
A novel method for the quantitation of yonkenafil, a new synthetic phosphodiesterase V inhibitor, in rat plasma using high… Expand